Skip to content
2000
Volume 18, Issue 19
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Kit is a growth factor receptor of the type III tyrosine kinase family, whose gain-of-function mutations have been identified as driving causes of different kinds of tumours. It thus represents a viable drug target, and the development of Kit inhibitors has been shown to be a promising therapeutic concept. This review will focus on structural and signalling properties of both wild-type and mutant Kit, as well as its role in the development of human cancers. Special attention will be dedicated to gastrointestinal stromal tumours, GISTs. Progress in research on the aetiopathogenesis of GISTs and their therapeutic approaches will be fully discussed, focusing on the latest tendencies for the treatment of these kinds of tumours.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986711796150504
2011-06-01
2025-05-03
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986711796150504
Loading

  • Article Type:
    Research Article
Keyword(s): GISTs; Kit; tyrosine kinase inhibitors
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test